Mainz Biomed (NASDAQ:MYNZ) Trading 0.7% Higher – Still a Buy?

Mainz Biomed NV (NASDAQ:MYNZ)’s share price traded up 0.7% during trading on Thursday . The company traded as high as $0.4898 and last traded at $0.4770. 60,899 shares were traded during mid-day trading, a decline of 93% from the average session volume of 832,986 shares. The stock had previously closed at $0.4738.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MYNZ shares. Wall Street Zen upgraded Mainz Biomed to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings reissued a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. Finally, Maxim Group lowered Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

Mainz Biomed Trading Down 4.0%

The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44. The business’s 50-day simple moving average is $0.80 and its 200-day simple moving average is $1.14. The company has a market cap of $4.15 million, a PE ratio of -0.01 and a beta of 0.31.

Institutional Investors Weigh In On Mainz Biomed

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC lifted its stake in shares of Mainz Biomed by 45.0% during the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after acquiring an additional 88,400 shares during the period. Cerity Partners LLC acquired a new stake in Mainz Biomed in the fourth quarter worth about $183,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in Mainz Biomed by 200.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares during the last quarter.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.